ID: ALA3233838

Max Phase: Preclinical

Molecular Formula: C23H20N4O2

Molecular Weight: 384.44

Molecule Type: Small molecule

Representations

Canonical SMILES:  N#C[C@@H]1CCCN1C(=O)CNC(=O)c1ccnc2cccc(-c3ccccc3)c12

Standard InChI:  InChI=1S/C23H20N4O2/c24-14-17-8-5-13-27(17)21(28)15-26-23(29)19-11-12-25-20-10-4-9-18(22(19)20)16-6-2-1-3-7-16/h1-4,6-7,9-12,17H,5,8,13,15H2,(H,26,29)/t17-/m0/s1

Standard InChI Key:  KECCJDBJEXGJCW-KRWDZBQOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 384.44

Molecular Weight (Monoisotopic): 384.1586

AlogP: 3.15

#Rotatable Bonds: 4

Polar Surface Area: 86.09

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 2.72

CX LogP: 2.12

CX LogD: 2.12

Aromatic Rings: 3

Heavy Atoms: 29

QED Weighted: 0.75

Np Likeness Score: -0.85

References

1. Jansen K, Heirbaut L, Verkerk R, Cheng JD, Joossens J, Cos P, Maes L, Lambeir AM, De Meester I, Augustyns K, Van der Veken P..  (2014)  Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP).,  57  (7): [PMID:24617858] [10.1021/jm500031w]

2.  (2016)  FAP inhibitors, 

Source

Source(2):

• Scientific Literature
• BindingDB Database